- Home
- ALLO vs LE Comparison
ALLO vs LE Comparison
Compare ALLO & LE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- LE
- Stock Information
- Founded
- ALLO 2017
- LE 1963
- Country
- ALLO United States
- LE United States
- Employees
- ALLO N/A
- LE N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- LE Clothing/Shoe/Accessory Stores
- Sector
- ALLO Health Care
- LE Consumer Discretionary
- Exchange
- ALLO Nasdaq
- LE Nasdaq
- Market Cap
- ALLO 438.2M
- LE 419.7M
- IPO Year
- ALLO 2018
- LE N/A
- Fundamental
- Price
- ALLO $1.92
- LE $12.75
- Analyst Decision
- ALLO Strong Buy
- LE Strong Buy
- Analyst Count
- ALLO 10
- LE 2
- Target Price
- ALLO $10.06
- LE $20.00
- AVG Volume (30 Days)
- ALLO 3.0M
- LE 122.1K
- Earning Date
- ALLO 11-07-2024
- LE 12-05-2024
- Dividend Yield
- ALLO N/A
- LE N/A
- EPS Growth
- ALLO N/A
- LE N/A
- EPS
- ALLO N/A
- LE N/A
- Revenue
- ALLO $43,000.00
- LE $1,436,124,000.00
- Revenue This Year
- ALLO N/A
- LE N/A
- Revenue Next Year
- ALLO N/A
- LE $1.97
- P/E Ratio
- ALLO N/A
- LE N/A
- Revenue Growth
- ALLO 26.47
- LE N/A
- 52 Week Low
- ALLO $1.78
- LE $7.64
- 52 Week High
- ALLO $5.78
- LE $19.88
- Technical
- Relative Strength Index (RSI)
- ALLO 39.98
- LE 36.11
- Support Level
- ALLO $2.11
- LE $12.93
- Resistance Level
- ALLO $2.40
- LE $14.12
- Average True Range (ATR)
- ALLO 0.17
- LE 0.54
- MACD
- ALLO 0.00
- LE 0.02
- Stochastic Oscillator
- ALLO 15.79
- LE 31.84
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically, it derives a majority of its revenue from the United States.